<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/CINECAstyle.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-22T11:45:51Z</responseDate><request verb="GetRecord" identifier="oai:iris.unica.it:11584/266580" metadataPrefix="oai_dc">https://iris.unica.it/oai/request</request><GetRecord><record><header><identifier>oai:iris.unica.it:11584/266580</identifier><datestamp>2022-10-15T14:46:47Z</datestamp><setSpec>com_11584_207615</setSpec><setSpec>com_11584_111066</setSpec><setSpec>col_11584_265854</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>La Metabolomica: una nuova era in Cardiologia.&#xd;
Le nostre esperienze originali nei campi dell' insufficienza cardiaca, della cardiopatia ischemica e dell' ipertensione polmonare</dc:title>
<dc:creator>DEIDDA, MARTINO</dc:creator>
<dc:subject>cardiopatia ischemica</dc:subject>
<dc:subject>coronary artery disease</dc:subject>
<dc:subject>heart failure</dc:subject>
<dc:subject>ipertensione polmonare</dc:subject>
<dc:subject>metabolomica</dc:subject>
<dc:subject>metabolomics</dc:subject>
<dc:subject>pulmonary hypertension</dc:subject>
<dc:subject>scompenso cardiaco</dc:subject>
<dc:subject>Settore MED/11 - Malattie dell'Apparato Cardiovascolare</dc:subject>
<dc:description>Purpose. Metabolomics (MBS) is a “omics” science that enables the assessment of a broad range of&#xd;
metabolites providing a metabolic picture able to identify metabolic changes. On these basis we&#xd;
carried out a metabolomics on three settings of cardiovascular diseases: a) heart failure; b) Stable&#xd;
coronary artery disease; c) Pulmonary hypertension in systemic sclerosis.&#xd;
Heart Failure&#xd;
Heart failure (HF) is characterized by a series of maladaptive metabolic changes, which have&#xd;
recently been proposed as a new therapeutic target.&#xd;
A proton nuclear magnetic resonance (1H NMR)-based MBS analysis was performed on blood&#xd;
samples of 3 groups of individuals: nine control individuals (Group A); nine HF patients with mildmoderate&#xd;
impairment of left ventricle ejection fraction (LVEF 35-50%; Group B); fifteen HF&#xd;
patients with severe LVEF impairment (EF &lt;35%; Group C). Specimens were analyzed with a 1HNMR&#xd;
500MHz spectrometer. A supervised PLS-DA Projection on Latent Structures Discriminant&#xd;
Analysis was applied to realize a descriptive model of HF. Morevoer, we carried out an&#xd;
echocardiographic evaluation of whole study population, including an assessment of Longitudinal&#xd;
Strain (S) and Strain Rate (SR) values using Speakle Tracking Imaging. The three groups showed a&#xd;
progressive impairment of systolic function from Group A to Group C, with intermediate values in&#xd;
Group B. The application of Pattern-recognition methods to 1H-NMR spectra identified 3 metabolic&#xd;
clusters related to A, B and C groups, respectively. The discrimination were related to a metabolic&#xd;
fingerprint depending on a limited set of metabolites. Our preliminary data show that MBS is a&#xd;
sensitive method, which can be effectively used in association with traditional techniques for the&#xd;
evaluation of HF. This new tool may permit to investigate the perturbed metabolic pathways in HF&#xd;
and their correlation with impaired myocardial function and could lead to the identification of&#xd;
innovative therapeutic approaches.&#xd;
Stable coronary artery disease&#xd;
Endothelial dysfunction is a key variable in the pathogenesis and progression of atherosclerosis and&#xd;
its complications, particullary coronary artery disease (CAD). Current evidence suggests that&#xd;
endothelial status is not determined solely by the individual risk factor burden but rather, may be&#xd;
regarded as an integrated index of all atherogenic and atheroprotective factors present in an&#xd;
individual. A 1H-NMR based MBS analysis was performed on (right and left) coronary blood&#xd;
samples of 11 subjects (7 male, 4 female; mean age 66+/-12,87 years) enrolled after a stress&#xd;
echocardiography suggestive for ischemia and undergone a coronary angiography (CA). On the&#xd;
basis of the results of CA we classified patients in two groups: occlusive coronary atherosclerosis&#xd;
(OCA) and microvascular disease (MD). A supervised Orthogonal Projection on Latent Structures&#xd;
Discriminant Analysis (OPLS-DA) was applied to evaluate whether it is possible to realize a&#xd;
descriptive model of the two different expressions of CAD. CA showed an OCA in 6 patients and a&#xd;
MD in the other 5. OPLS-DA identified two clusters related to the CA groups, achieving good&#xd;
values of R2 (R2y=0.994) and Q2 (Q2=0.905); these components featured a significant separation as&#xd;
determined by ANOVA cross-validation (p&lt;0.01). The metabolites of major importance in&#xd;
determining clustering were: Alanine, Beatine, N-N-Dimethyl-glycine, Citrate, Lactate, Malonate,&#xd;
Piruvate and Succinate. Afterwards, we applied an univariate statistical analysis to evaluate the&#xd;
differences in concentration of these metabolites between groups; this analysis showed betaine and&#xd;
DMG higher levels in patients with OCA when compared with those affected by MD&#xd;
(0.3573±0.2324 μM vs 0.1340±0.1040 μM, p&lt;0.03, and 0.0064±0.0032 μM vs 0.0030±0.0014 μM,&#xd;
p&lt;0.02, respectively). It is remarkable that these two metabolites are are related to the NO&#xd;
metabolism and the endothelial function. MBS seems to be a sensitive method, which can be&#xd;
effectively used in the study of CAD pathophysiology. The obtained results, if confirmed, could be&#xd;
the basis of future researches on the role of vascular microambient in determinig the evolution of&#xd;
atherosclerosis in the two different pathophysiological settings and could lead to the identification&#xd;
of innovative therapeutic approaches.&#xd;
Pulmonary hypertension (PH) in systemic sclerosis (SS)&#xd;
Pulmonary hypertension (PH) in systemic sclerosis (SS) identifies a poor prognosis subset of&#xd;
patients. Recent studies suggested a “metabolic theory” on the development of pulmonary arterial&#xd;
hypertension. On these basis we carried out a metabolomics study in order to evaluate whether in&#xd;
SS patients with increased Pulmonary Vascular Resistance (PVR) differences in pulmonary arterial&#xd;
blood metabolites were identifiable. We studied 18 SS patients (age 58,7±15,6 years) free of&#xd;
pulmonary fibrosis that underwent a clinical evaluation, a standard echocardiography with Tissue&#xd;
Doppler and Speckle tracking Imaging and a right heart catheterization (RHC). A blood sample was&#xd;
collected during the RHC in the distal peripheral circulation of the pulmonary arteries to perform&#xd;
the metabolomic analysis. Specimens were analyzed with a 1H-NMR 500MHz spectrometer. An&#xd;
Orthogonal Signal Correction (OSC) and a Projection on Latent Structures Discriminant Analysis&#xd;
(PLS-DA) were applied. Based on PVR we divided the population in Group A (N=8; PVR&lt;1.6 uW;&#xd;
mean±SD = 1,16±0,23 uW) and Group B (N=10; PVR>1.6 uW; mean±SD = 2,67±0,67 uW.&#xd;
p&lt;0.001 vs Group A). No significant differences were identified in terms of anthropometric,&#xd;
clinical, echo and terapeutic characteristics. At RHC the 2 groups showed a difference in mean&#xd;
pulmonary pressures values (Group A: 20±4 mmHg; Group B: 25±5 mmHg), with mild PH in&#xd;
group B. We applied an OSC using NMR data as the X-matrix and PVR values as the Y-matrix. A&#xd;
clear clusterization was observed with the PLS-DA, achieving good values of R2 (R2X=0.364;&#xd;
R2Y=0.889) and Q2 (0.721), with significative ANOVA cross-validation (p=0.003). The&#xd;
discrimination were related to a metabolic fingerprint depending on a limited set of metabolites:&#xd;
Group B was characterized by higher values of Lactate, Glycerol, fatty acids, Acetoacetate, Valine,&#xd;
Leucine, Isoleucine and VLDL/LDL, whereas Group A showed higher values of Choline, Betaine,&#xd;
Alanine, Glycine, Taurine, Arginine and 3-OH-butyrate; is worthy of note that all the compounds&#xd;
relatively higher in Group A are related to the NO metabolism and the endothelial function.&#xd;
Increased PVR seems to be related to specific metabolites strictly connected to the endothelial&#xd;
dysfunction. Moreover MBS showed to be capable to finely identify the metabolic imbalance of&#xd;
vasoactive factors able to determine and maintain the increased PVR. This approach could prove to&#xd;
be useful in better understanding the pathophysiology of this severe complication of SS.</dc:description>
<dc:date>2015-04-15</dc:date>
<dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
<dc:identifier>http://hdl.handle.net/11584/266580</dc:identifier>
<dc:language>ita</dc:language>
<dc:relation>numberofpages:116</dc:relation>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:publisher>Università degli Studi di Cagliari</dc:publisher>
<dc:rights>license:Non specificato</dc:rights>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>